HuMax-IL8
Phase 2Small molecule
Bristol-Myers SquibbHuMax-IL8 is one of 30 small molecule programs targeting Neoadjuvant. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Neoadjuvant
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Gemzar
Johnson & JohnsonPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Tagrisso
AstraZenecaPhase 2
Verzenio
Eli LillyPhase 2
Lenvima
EisaiPhase 2
Ellence
PfizerPhase 2
Nubeqa
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Neoadjuvant1 trial
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04848116·24 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HuMax-IL8. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company